Document





 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)
April 28, 2020
SHARPS COMPLIANCE CORP.
Commission File No. 001-34269

(Exact Name Of Registrant As Specified In Its Charter)
 
 
 
Delaware
(State Or Other Jurisdiction Of
Incorporation Or Organization)
 
74-2657168
(IRS Employer
Identification No.)
9220 Kirby Drive, Suite 500
Houston, Texas 77054
(Address Of Principal Executive Offices)

Registrant’s Telephone Number, Including Area Code)
713-432-0300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol
Name of Each Exchange on Which Registered
Common Shares, $0.01 Par Value
SMED
The NASDAQ Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
 






TABLE OF CONTENTS
Item 2.02      Disclosure of Results of Operations of Financial Condition

Item 9.01      Financial Statements and Exhibits

SIGNATURES

INDEX TO EXHIBITS

Press Release





















































Item 2.02. Results of Operations and Financial Condition.
On April 28, 2020 , the Company announced its results of operations for the three and nine months ended March 31, 2020 . A copy of the earnings release is attached as Exhibit 99.1.
The information in this Current Report is being furnished pursuant to Item 2.02 including Exhibit 99.1 of Form 8-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), and Section 11 of the Securities Act of 1933, as amended, otherwise subject to the liabilities of those sections nor incorporated by reference in any filing under the Exchange Act unless specifically referenced in such subsequent filing as being incorporated by reference. The Company does not undertake a duty to update the information in this Current Report and cautions that the information included in this Current Report is current only as of April 28, 2020 and may change thereafter.


Item 9.01. Financial Statements and Exhibits.
(a)
Financial Information
Not applicable.
(b)
Pro Forma Financial Information
Not applicable.
(c)
Exhibits
Exhibit          Description
99.1          Press Release, dated April 28, 2020 .

    







SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 28, 2020
SHARPS COMPLIANCE CORP.


By:   /s/ DIANA P. DIAZ
Diana P. Diaz
Vice President and Chief Financial Officer








INDEX TO EXHIBITS

Exhibit Number
Description









Exhibit


EXHIBIT 99.1
IMMEDIATE RELEASE
    

Sharps Compliance Reports Fiscal 2020 Third Quarter Results
Third quarter 2020 revenue of $10.4 million, an increase of 10% over prior year
Unused medications billings grew 24%
Route-based billings increased 16%
Billings increased in several key markets including Retail at 46%, Professional at 6% and Assisted Living at 20%
Increasing medical waste processing capacity from 10 million to 27 million pounds per year by September 2020
Preparing for strong flu and potential COVID-19 immunization seasons through a significant increase in inventory of medical waste mailbacks and additional distribution facility space
Route-based business footprint extends to 32 states, or 70% of the population, significantly increasing the Company’s pipeline of larger small and medium quantity generator new prospect opportunities


HOUSTON, Texas, April 28, 2020 - Sharps Compliance Corp. (NASDAQ: SMED) (“Sharps” or the “Company”), a leading full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous, today reported financial results for the third quarter and first nine months of fiscal year 2020 ended March 31, 2020.
Revenue in the third quarter of fiscal 2020 was $10.4 million, an increase of 10% compared to $9.5 million in the same prior year quarter. Customer billings increased 9% to $10.3 million for the third quarter compared to $9.5 million for the same prior year quarter. Third quarter 2020 gross margin remained consistent at 21% as compared the third quarter of fiscal 2019. SG&A increased 24% to $3.6 million or 35% of revenue in the third quarter of fiscal 2020, as compared to SG&A of $2.9 million, or 31% of revenue in the same prior year quarter. The increase in SG&A is related to the Company’s continued investments in sales and marketing as well as increased professional fees incurred during fiscal 2020, including the third quarter.
The Company reported an operating loss of $1.6 million in the third quarter of 2020, compared to an operating loss of $1.1 million in the third quarter of 2019. Sharps recorded a net loss of $1.6 million, or a loss of $0.10 per basic and diluted share in the third quarter of fiscal 2020, as compared to a net loss of $1.1 million, or $0.07 per basic and diluted share in the third quarter of fiscal 2019. Sharps recorded an EBITDA loss of $1.2 million in the third quarter of fiscal 2020, as compared to an EBITDA loss of $0.6 million in the third quarter of fiscal 2019. (See Reconciliation of Net Income (Loss) to EBITDA in the supplemental table included at the end of this release).





David P. Tusa, President and Chief Executive Officer of Sharps, stated, “As we report our third quarter results, our country and the entire world are coping with the devastating health and economic impacts of COVID-19. At Sharps Compliance, we’re taking every precaution to ensure the safety of our employees, while at the same time remaining active as a leading national provider of comprehensive medical waste solutions, bringing uninterrupted essential support to our customers and the healthcare industry. In support of this, we increased our route-based drivers, plant and operations personnel by ten percent (10%) in advance of the COVID-19 pandemic to make sure that our operations and servicing of customers would not be adversely affected by the potential absence of employees due to COVID-19. We also temporarily increased the pay for our front-line operations personnel and drivers during the pandemic.”
Growth Opportunities and Infrastructure Build Out
As announced on March 25, 2020, the Company is focused on expanding its infrastructure to support what it believes will be a strong 2020 flu and immunization season as well as medical waste disposal related to a potential COVID-19 vaccine which may become available for administration in the U.S. Additionally, the Company sees other potential increased medical waste volumes related to COVID-19 such as the long-term care market where personal protective equipment, or PPE, in many facilities is being disposed of as medical waste and not as trash which has been the historical practice. Finally, the Company’s route-based footprint now extends to 32 states, or 70% of the population, significantly increasing the pipeline of larger small and medium quantity generator sales opportunities.
To address these opportunities, the Company is:
Significantly increasing its production and inventory of medical waste mailback and shipback solutions to ensure it remains well positioned to meet an expected increase in customer demand related to the 2020 season flu and the potential COVID-19 vaccine;
Increasing its medical waste processing capacity from 10 million to 27 million pounds per year through the addition of a larger autoclave at its Texas facility as well as an additional autoclave at its Pennsylvania facility;
Securing a larger warehouse and distribution facility in Pennsylvania to store and distribute larger volumes of medical waste mailbacks; and
Expanding its route-based truck fleet and drivers necessary to facilitate the potential increase in volumes from its expanded 32 state route-based footprint and related larger prospect opportunities.

Tusa added, "Regarding the quarter, March is typically our slowest revenue quarter as a result of seasonality and customer ordering patterns. In spite of this, we achieved growth in revenue with increased customer billings in our retail, professional, and assisted living markets and substantial growth in two of our three key solutions - unused medication management and route-based, with our traditional mailback offering essentially flat for the quarter. We expected higher gross margins for the March 2020 quarter, but the cost of goods sold for the quarter was adversely impacted by the proactive 10% increase in route-based drivers, plant and operations personnel and by the pay increase for frontline workers we implemented to ensure uninterrupted service during the COVID-19 pandemic, as mentioned above. Additionally, we incurred operations costs related to the expansion of the route-based business into the Midwest ahead of the anticipated revenue. All of these efforts increased cost of goods sold for the quarter by about $200,000, or about 200 basis points."





Third Quarter Review
Retail market billings increased 46% to $2.3 million in the third quarter of fiscal 2020 as compared to $1.6 million in the same prior year period. The increase in retail billings is primarily due to an acceleration in flu shot related orders and increased unused medication billings including both MedSafe and TakeAway Medication Recovery System envelopes.
Professional market billings increased 6% to $3.9 million in the third quarter of fiscal 2020 compared to $3.7 million in the prior year period. Sharps has driven organic growth in this segment by providing a combination of its cost-effective and easy to use Sharps Recovery System™ and route-based pick-up services, which has been attractive to the small to medium quantity waste generator market comprised of physicians, clinics, dentists, surgery centers, labs, veterinarians and other healthcare providers. Billings for the inside and online sales channel, which primarily targets the Professional and Government markets, increased 28% to $2.5 million in the third quarter of fiscal 2020 as compared to $2.0 million in the same prior year period.
Assisted Living billings increased 20% to $0.8 million in the third quarter of fiscal 2020 compared to $0.6 million in the prior year period, related primarily to increased unused medication billings and COVID-19 related waste management.
Pharmaceutical Manufacturer billings decreased 17% to $0.9 million in the third quarter of fiscal 2020 compared to $1.0 million in the third quarter of fiscal 2019, related to the timing of inventory builds for patient support programs.
First Nine Months Results
Sharps recorded revenue of $38.6 million in the first nine months of 2020, an increase of 20% compared to revenue of $32.1 million in the first nine months of 2019. Customer billings increased 22% to $39.5 million in the first nine months of fiscal 2020. Retail billings increased 33% to $10.7 million as compared to $8.0 million in the first nine months of fiscal 2019, due primarily to an increase in billings for unused medications including MedSafe and TakeAway Medication Recovery System envelopes as well as flu shot related orders. Home Health Care billings increased 32% to $7.6 million in the first nine months of fiscal 2020 compared to $5.7 million in the same period of 2019. In the first nine months of fiscal 2020, Pharmaceutical Manufacturer billings increased 52% to $4.1 million as compared to $2.7 million in the first nine months of fiscal 2019. Professional billings increased 11% to $12.4 million in the first nine months of fiscal 2020 as compared to $11.2 million in the prior year period. 
Gross margin increased to 30% for the first nine months of fiscal 2020 as compared to 29% in the first nine months of fiscal 2019. SG&A expense increased 21% to $10.7 million compared to $8.9 million in the first nine months of 2019, related to the Company’s continued investments in sales and marketing, but was consistent with the prior year as a percentage of sales at 28%. The Company recorded operating income of $0.3 million in the first nine months of fiscal 2020 as compared to an operating loss of $0.1 million in the first nine months of fiscal 2019.
Net income for the first nine months of 2020 was $0.1 million, or $0.01 per basic and diluted share compared to a net loss of $0.3 million or a loss of $0.02 per basic and diluted share in the first nine months of fiscal 2019.
Sharps recorded improved EBITDA of $1.5 million in the first nine months of fiscal 2020, as compared to EBITDA of $1.1 million in the first nine months of fiscal 2019. (See Reconciliation of Net Income (Loss) to EBITDA in the supplemental table included at the end of this release).








Financial Flexibility and a Strong Balance Sheet
Cash was $4.9 million at March 31, 2020, compared to cash of $4.5 million at June 30, 2019. The Company had working capital of $9.7 million at March 31, 2020 compared to working capital of $10.6 million at June 30, 2019. Additionally, the Company recently announced that it received loan proceeds of $2.2 million on April 20, 2020 under the Paycheck Protection Program (“PPP”) under a promissory note from its commercial bank. The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after eight weeks providing that the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels.
Mr. Tusa concluded, “As an essential service provider to healthcare, we believe we have improved revenue visibility over the next twelve to eighteen months and we anticipate that revenues could be favorably impacted by what experts believe could be a strong flu immunization season, potentially followed by a COVID-19 immunization effort, coupled with potential growth from our core markets including long-term care, home healthcare and the professional markets. Additionally, the expansion of our route-based footprint coverage to 32 states, or 70% of the population, significantly increases the pipeline of new prospect opportunities of larger small and medium quantity generators. We are confident that our leadership position as a comprehensive provider of medical, pharmaceutical and hazardous waste to small to medium quantity generators will provide diverse opportunities for the growth of our business through the balance of fiscal 2020 and beyond.”
Third Quarter Fiscal Year 2020 Webcast and Conference Call
The Company will host a teleconference today beginning at 11:00 a.m. Eastern Time, during which management will review the financial and operating results for the period and discuss Sharps’ corporate strategy and outlook. A question-and-answer session will follow.
The Sharps conference call can be accessed by domestic callers by dialing (877) 407-0782. International callers may access the call by dialing (201) 689-8567. The webcast can be monitored at www.sharpsinc.com.
A telephonic replay will be available through May 28, 2020. To listen to the replay, domestic callers should dial (877) 481-4010 and international callers should dial (919) 882-2331 and enter replay ID number 34131. Transcript will also be posted to the Sharps website, once available.





About Sharps Compliance Corp.
Headquartered in Houston, Texas, Sharps Compliance is a leading full-service national provider of comprehensive waste management services including medical, pharmaceutical and hazardous. Its key markets include healthcare facilities, pharmaceutical manufacturers, home healthcare providers, assisted living / long-term care, surgery centers, retail pharmacies and clinics, and the professional market which is comprised of physicians, dentists and veterinary practices. The Company's flagship product, the Sharps Recovery System, is a comprehensive solution for the containment, transportation, treatment and tracking of medical waste and other used healthcare materials. The Company also offers its route-based pick-up service in a thirty-two (32) state region of the South, Southeast, Midwest and Northeast portions of the United States. Sharps also provides two simple solutions for safe and easy disposal of unused medications: MedSafe collection receptacles and TakeAway Medication Recovery System Envelopes.
More information on the Company and its products can be found on its website at: www.sharpsinc.com.
Safe Harbor Statement
The information made available in this news release contains certain forward-looking statements which reflect Sharps Compliance Corp.'s current view of future events and financial performance. Wherever used, the words "estimate," "expect," "plan," "anticipate," "believe," "may" and similar expressions identify forward-looking statements. Any such forward-looking statements are subject to risks and uncertainties and the company's future results of operations could differ materially from historical results or current expectations. Some of these risks include, without limitation, the company's ability to educate its customers, development of public awareness programs to educate the identified consumer, customer preferences, the Company's ability to scale the business and manage its growth, the degree of success the Company has at gaining more large customer contracts, managing regulatory compliance and/or other factors that may be described in the company's annual report on Form 10-K, quarterly reports on Form 10-Q and/or other filings with the Securities and Exchange Commission. Future economic and industry trends that could potentially impact revenue and profitability are difficult to predict. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future chang es make it clear that any projected results, express or implied therein, will not be realized.
Non-GAAP Measures
This release contains certain financial information not derived in accordance with generally accepted accounting principles (“GAAP”), including customer billings information and EBITDA. The Company believes this information is useful to investors and other interested parties. EBITDA is a significant performance metric used by management and by external users of our financial statements such as investors, research analysts and others to assess the financial performance of our assets without regard to financing methods, capital structure or historical cost basis; the ability of our assets to generate cash sufficient to pay interest costs and support our indebtedness; and our operating performance and return on capital as compared to those of other companies in our industry. Such information should not be considered as a substitute for any measure derived in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Reconciliation of this information to the most comparable GAAP measures is included as an attachment to this release.








For more information contact:
 

Diana P. Diaz
Sharps Compliance Corp.
Vice President and Chief Financial Officer
Phone: (713) 660-3547
Email: ddiaz@sharpsinc.com
John Nesbett/Jennifer Belodeau
IMS Investor Relations
Phone: (203) 972-9200
Email: jnesbett@institutionalms.com

FINANCIAL TABLES FOLLOW






Sharps Compliance Corp. and Subsidiaries
Condensed Consolidated Statements of Operations
(in thousands, except per share data )
(Unaudited)

 
Three-Months Ended
 
 
Nine-Months Ended
 
 
March 31,
 
 
March 31,
 
 
2020
 
2019
% Change
 
2020
 
2019
% Change
 
 
 
 
 
 
 
 
 
 
Revenue
$
10,414

 
$
9,451

10.2%
 
$
38,578

 
$
32,138

20.0
%
 
 
 
 
 
 
 
 
 
 
Cost of revenue
8,191

 
7,416

10.5%
 
26,999

 
22,760

18.6
%
Gross profit
2,223

 
2,035

9.2%
 
11,579

 
9,378

23.5
%
Gross margin
21.3
 %
 
21.5
 %
 
 
30.0
%
 
29.2
 %
 
SG&A expense
3,600

 
2,901

24.1%
 
10,718

 
8,886

20.6
%
Depreciation and amortization
201

 
207

 
 
602

 
613

 
 
 
 
 
 
 
 
 
 
 
Operating Income (Loss)
(1,578
)
 
(1,073
)
 
 
259

 
(121
)
 
Operating margin
(15.2
)%
 
(11.4
)%
 
 
0.7
%
 
(0.4
)%
 
 
 
 
 
 
 
 
 
 
 
Interest income
4

 
5

 
 
13

 
18

 
Interest expense
(36
)
 
(22
)
 
 
(81
)
 
(68
)
 
Total other expense
(32
)
 
(17
)
 
 
(68
)
 
(50
)
 
 
 
 
 
 
 
 
 
 
 
Income (loss) before income tax expense
(1,610
)
 
(1,090
)
 
 
191

 
(171
)
 
Income tax expense (benefit)
(54
)
 
35

 
 
91

 
105

 
Net Income (Loss)
$
(1,556
)
 
$
(1,125
)
 
 
$
100

 
$
(276
)
 
 
 
 
 
 
 
 
 
 
 
Net Income (Loss) Per Share
 
 
 
 
 
 
 
 
 
     Basic and diluted
$
(0.10
)
 
$
(0.07
)
 
 
$
0.01

 
$
(0.02
)
 
 
 
 
 
 
 
 
 
 
 
Weighted Average Shares Outstanding
 
 
 
 
 
 
 
 
 
Basic
16,264

 
16,138

 
 
16,211

 
16,107

 
Diluted
16,264

 
16,138

 
 
16,312

 
16,107

 





Sharps Compliance Corp. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands)
(Unaudited)
 
 
 
 
 
March 31,
 
June 30,
 
2020
 
2019
 
 
 
 
ASSETS:
 
 
 
Current assets:
 
 
 
Cash
$
4,898

 
$
4,512

Accounts receivable, net
9,565

 
9,289

Inventory
4,910

 
3,770

Contract asset
55

 
260

Prepaid and other current assets
1,616

 
922

Total current assets
21,044

 
18,753

Property, plant and equipment, net
7,673

 
5,867

Operating lease right of use asset
8,555

 

Inventory, net of current portion
927

 
1,046

Other assets
449

 
443

Goodwill
6,735

 
6,735

Intangible assets, net
2,857

 
3,196

Total assets
$
48,240

 
$
36,040

 
 
 
 
 
 
 
 
LIABILITIES AND STOCKHOLDERS' EQUITY:
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
3,249

 
$
2,946

Accrued liabilities
2,449

 
2,213

Operating lease liability
2,021

 

Current maturities of long-term debt
626

 
517

Contract liability
3,017

 
2,502

Total current liabilities
11,362

 
8,178

Contract liability, net of current portion
730

 
503

Operating lease liability, net of current portion
6,655

 

Other liabilities
120

 
42

Deferred tax liability
454

 
243

Long-term debt, net of current portion
1,745

 
948

Total liabilities
21,066

 
9,914

Stockholders’ equity
27,174

 
26,126

Total liabilities and stockholders' equity
$
48,240

 
$
36,040






Sharps Compliance Corp. and Subsidiaries
Supplemental Customer Billing and Revenue Information
(in thousands)
(Unaudited)

 
 
Three-Months Ended March 31,
 
 
 
2020
 
% Total
 
2019
 
$ Change
 
%
 
BILLINGS BY MARKET:
 
 
 
 
 
 
 
 
 
 
 
Professional

$
3,885


37.7
%

$
3,657


$
228


6.2%
 
Retail
 
2,314

 
22.4
%
 
1,590

 
724

 
45.5%
 
Home Health Care

1,663


16.1
%

1,640


23


1.4%
 
Pharmaceutical Manufacturer
 
857

 
8.3
%
 
1,034

 
(177
)
 
(17.1)%
 
Assisted Living
 
758

 
7.3
%
 
632

 
126

 
19.9%
 
Government

571


5.5
%

568


3


0.5%
 
Environmental
 
38

 
0.4
%
 
25

 
13

 
52.0%
 
Other
 
240

 
2.3
%
 
335

 
(95
)
 
(28.4)%
 
Subtotal
 
10,326

 
100.0
%
 
9,481

 
845

 
8.9%
 
GAAP Adjustment *
 
88

 
 
 
(30
)
 
118

 
 
 
Revenue Reported
 
$
10,414

 
 
 
$
9,451

 
$
963

 
10.2%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nine-Months Ended March 31,
 
 
 
2020
 
% Total
 
2019
 
$ Change
 
%
 
BILLINGS BY MARKET:
 
 
 
 
 
 
 
 
 
 
 
Professional
 
$
12,385

 
31.5
%
 
$
11,159

 
$
1,226

 
11.0
 %
 
Retail
 
10,674

 
27.0
%
 
8,002

 
2,672

 
33.4
 %
 
Home Health Care
 
7,586

 
19.2
%
 
5,728

 
1,858

 
32.4
 %
 
Pharmaceutical Manufacturer
 
4,068

 
10.3
%
 
2,684

 
1,384

 
51.6
 %
 
Assisted Living
 
2,063

 
5.2
%
 
1,897

 
166

 
8.8
 %
 
Government
 
1,824

 
4.6
%
 
1,708

 
116

 
6.8
 %
 
Environmental
 
123

 
0.3
%
 
206

 
(83
)
 
(40.3
)%
 
Other
 
752

 
1.9
%
 
874

 
(122
)
 
(14.0
)%
 
Subtotal
 
39,475

 
100.0
%
 
32,258

 
7,217

 
22.4
 %
 
GAAP Adjustment*
 
(897
)
 
 
 
(120
)
 
(777
)
 
 
 
Revenue Reported
 
$
38,578

 
 
 
$
32,138

 
$
6,440

 
20.0
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Represents the net impact of the revenue recognition adjustments to arrive at reported GAAP revenue. Customer billings include all invoiced amounts for products shipped or services rendered during the period reported. GAAP revenue includes customer billings as well as numerous adjustments necessary to reflect, (i) the deferral of a portion of current period sales, (ii) recognition of certain revenue associated with product returned for treatment and destruction and (iii) provisions for certain product returns and discounts to customers which are accounted for as reductions in sales in the same period the related sales are recorded. Most of the difference between customer billings and GAAP revenue is reflected in the Company’s balance sheet as Contract Liability.






Sharps Compliance Corp. and Subsidiaries
Supplemental Customer Billing by Solution Information
(in thousands)
(Unaudited)

 
 
Three-Months Ended March 31,
 
 
2020
 
% Total
 
2019
 
$ Change
 
%
BILLINGS BY SOLUTION:
 
 
 
 
 
 
 
 
 
Mailbacks
$
4,614

 
44.7
%
 
$
4,607

 
$
7

 
0.2%
Route-Based Pickup
2,625

 
25.4
%
 
2,259

 
366

 
16.2%
Unused Medications
2,111

 
20.4
%
 
1,705

 
406

 
23.8%
Third Party Treatment
38

 
0.4
%
 
26

 
12

 
46.2%
Other
 
938

 
9.1
%
 
884

 
54

 
6.1%
Total Billings By Solution
$
10,326

 
100.0
%
 
$
9,481

 
$
845

 
8.9%
 
 
 
 
 
 
 
 
 
 
 
 
 
Nine-Months Ended March 31,
 
 
2020
 
% Total
 
2019
 
$ Change
 
%
BILLINGS BY SOLUTION:
 
 
 
 
 
 
 
 
 
Mailbacks
$
21,280

 
53.8
%
 
$
18,343

 
$
2,937

 
16.0
 %
Route-Based Pickup
7,762

 
19.7
%
 
6,465

 
1,297

 
20.1
 %
Unused Medications
6,815

 
17.3
%
 
4,694

 
2,121

 
45.2
 %
Third Party Treatment
123

 
0.3
%
 
206

 
(83
)
 
(40.3
)%
Other
 
3,495

 
8.9
%
 
2,550

 
945

 
37.1
 %
Total Billings By Solution
$
39,475

 
100.0
%
 
$
32,258

 
$
7,217

 
22.4
 %
 
 
 
 
 
 
 
 
 
 
 





Sharps Compliance Corp. and Subsidiaries
Supplemental Customer Billing by Channel Information
(in thousands)
(Unaudited)
 
 
 
 
 
 
 
 
 
 
 
 
 
Three-Months Ended March 31,
 
 
2020
 
% Total
 
2019
 
$ Change
 
% Change
BILLINGS BY CHANNEL:
 
 
 
 
 
 
 
 
 
 
Direct Sales
 
$
5,276

 
51.1
%
 
$
5,110

 
$
166

 
3.2%
Distributors
 
2,501

 
24.2
%
 
2,377

 
124

 
5.2%
Inside and Online Sales
 
2,549

 
24.7
%
 
1,994

 
555

 
27.8%
Total Billings By Channel
 
$
10,326

 
100.0
%
 
$
9,481

 
$
845

 
8.9%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nine-Months Ended March 31,
 
 
2020
 
% Total
 
2019
 
$ Change
 
% Change
BILLINGS BY CHANNEL:
 
 
 
 
 
 
 
 
 
 
Direct Sales
 
$
21,505

 
54.5
%
 
$
16,563

 
$
4,942

 
29.8
%
Distributors
 
10,613

 
26.9
%
 
9,437

 
1,176

 
12.5
%
Inside and Online Sales
 
7,357

 
18.6
%
 
6,258

 
1,099

 
17.6
%
Total Billings By Channel
 
$
39,475

 
100.0
%
 
$
32,258

 
$
7,217

 
22.4
%
 
 
 
 
 
 
 
 
 
 
 
 





Sharps Compliance Corp. and Subsidiaries
Supplemental Table to Reconcile Net Income (Loss) to EBITDA*
(in thousands)
(Unaudited)

 
Three-Months Ended
 
Nine-Months Ended
 
March 31,
 
March 31,
 
2020
 
2019
 
2020
 
2019
 
 
 
 
 
 
 
 
Net Income (Loss)
$
(1,556
)
 
$
(1,125
)
 
$
100

 
$
(276
)
 
 
 
 
 
 
 
 
Income tax expense (benefit)
(54
)
 
35

 
91

 
105

Interest expense, net
32

 
17

 
68

 
50

Depreciation and amortization
388

 
426

 
1,191

 
1,233

 
 
 
 
 
 
 
 
EBITDA
$
(1,190
)
 
$
(647
)
 
$
1,450

 
$
1,112

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*The Company defines earnings before interest, taxes, depreciation and amortization (“EBITDA”) as net income (loss), plus income tax expense (benefit), net interest expense, and depreciation and amortization. Other companies may define EBITDA differently. EBITDA is presented because it is a financial measure that is frequently requested by third parties. However, EBITDA is not considered under generally accepted accounting principles as a primary measure of an entity’s financial results, and accordingly, EBITDA should not be considered an alternative to operating income (loss), net income (loss), or cash flows as determined under generally accepted accounting principles and as reported by the Company.